tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)

Reports Q2 revenue $39.5M, consensus $35.58M. “The second quarter marked a significant step forward in Phathom’s journey toward becoming a growth-oriented and profitable GI company,” said CEO Steve Basta. “We delivered strong sequential revenue growth, implemented strategic cost reductions, and shifted our commercial strategy to focus on high-value prescribers. With over 580,000 VOQUEZNA prescriptions filled to date and extended market exclusivity, we believe we are well-positioned to accelerate VOQUEZNA’s adoption and achieve profitability in 2026.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1